BMJ Open

Organisation and function of the primary motor cortex in chronic pain: protocol for a systematic review and meta-analysis

Wei-Ju Chang,¹ Neil E O’Connell,² Emma Burns,¹ Lucy S Chipchase,¹ Matthew B Liston,¹ Siobhan M Schabrun¹

ABSTRACT

Introduction: Primary motor cortical (M1) adaptation in the form of altered organisation and function is hypothesised to underpin motor dysfunction observed in chronic pain. The aim of this review is to assess the evidence for altered M1 organisation and function in chronic pain.

Methods and analysis: Systematic review and meta-analysis. We will search electronic databases with predetermined search terms to identify relevant studies and evaluate the studies for inclusion and risks of bias. Two independent reviewers will extract data. Any disagreement will be resolved through a third reviewer. Cross-sectional or prospective studies published in English before May 2015 that investigate M1 organisation and function in chronic pain will be included if they meet the eligibility criteria. Primary outcomes will include M1 cortical excitability, spatial cortical representation, the function of inhibitory and facilitatory intracortical networks, cortical reactivity and cortical glucose metabolism. Clinical measures such as pain and disability will be included where the correlation with the primary outcomes of M1 organisation and function were investigated in the included studies.

Ethics and dissemination: This systematic review does not require ethical approval. The results of this review will be submitted for peer-reviewed publication regardless of outcome and will be presented at relevant conferences.

Trial registration number: Our systematic review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD42015014823).

INTRODUCTION

Musculoskeletal disorders are a common cause of disability and result in significant social and economic costs.¹ An estimated 10%, 5% and 4% of the global population with low back pain (LBP), neck pain and knee osteoarthritis, respectively, live with chronic pain. The primary motor cortex (M1) is implicated in chronic pain. However, to the best of our knowledge, this is the first systematic review of M1 changes across multiple chronic pain conditions.

Movement dysfunction associated with pain is commonly observed in the clinic and is a key focus of rehabilitation. For instance, when musculoskeletal pain is present, deficits in force production, amplitude and speed of movement, muscle coordination and postural control are reported.³⁻⁵ Despite this, the physiological basis and clinical relevance of movement dysfunction in pain is poorly understood. There is considerable debate regarding the type, quantity and timing of movement-based treatments, if any, needed to effectively target motor dysfunction in persistent musculoskeletal pain disorders.⁶⁻⁸

The primary motor cortex (M1) is a key driver of motor output and may therefore contribute to movement dysfunction in pain, making it a potential target for therapy. There is emerging evidence of altered M1 organisation and function across a range of chronic pain conditions. For example, M1 topographical representations generated using transcranial magnetic stimulation (TMS) show greater overlap and a reduced
number of discrete peaks in chronic low back\textsuperscript{9–11} and elbow pain,\textsuperscript{12} and these changes are associated with pain severity and/or motor dysfunction. Similarly, there is evidence for increased signal with movement of the affected hand in complex regional pain syndrome (CRPS) using functional MRI\textsuperscript{13} and evidence of reduced GABAergic and glutamatergic M1 function in fibromyalgia that is associated with fatigue.\textsuperscript{14}

To our knowledge, only one published systematic review has investigated M1 organisation and function in chronic pain, and this was restricted to CRPS.\textsuperscript{15} That review revealed limited evidence of bilateral M1 disinhibition in CPRS of the upper limb.\textsuperscript{15} However, it is unknown whether similar alterations in M1 are present in other forms of chronic pain. Indeed, one previous study has suggested that M1 disinhibition may occur in chronic neuropathic but not chronic nociceptive pain.\textsuperscript{16}

This review will be the first to systematically and critically evaluate the evidence for altered M1 organisation and function, across a range of measurement tools, in chronic pain conditions of neuropathic and non-neuropathic origin. Understanding how M1 organisation and function is altered in chronic pain is essential to inform the design and testing of treatment strategies that seek to target M1 in pain.

Here, we present the protocol for a review that aims to evaluate the evidence for altered M1 organisation and function in chronic pain conditions of neuropathic or non-neuropathic origin. This protocol is prepared according to the Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines.\textsuperscript{17} The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD42015014823).

**METHODS AND ANALYSIS**

**Review question**

What is the evidence for altered M1 organisation and function in chronic pain conditions of neuropathic and non-neuropathic origin?

**Search strategy**

The methods for this systematic review have been developed according to the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies.\textsuperscript{18} The search strategy will be implemented in two stages.

1. Searches will be conducted in PubMed, MEDLINE, EMBASE, PsychINFO and CINAHL databases to identify relevant literature. Key words and medical subject headings (MeSH) related to chronic pain, neuroimaging and the brain will be used; for example: chronic pain, positron emission tomography, functional magnetic resonance imaging, BOLD contrast, Electroencephalography, Magnetoencephalography, transcranial magnetic stimulation, motor cortical and sensorimotor cortex. The full search terms are listed in online supplementary appendix 1. The combination of chronic pain, neuroimaging and brain search terms will be used in varying combinations to identify relevant literature. Search strategies will be customised to suit each database. The main search strategy is included in online supplementary appendix 1.

2. The reference lists of eligible articles and relevant reviews will be manually searched for additional articles.

**Type of participants**

Participants should be adults (aged over 18 years) experiencing chronic, musculoskeletal pain of neuropathic or non-neuropathic origin. Neuropathic pain is defined as ‘pain caused by a lesion or disease of somatosensory nervous system’.\textsuperscript{19} Non-neuropathic pain is defined as pain without an identifiable lesion or disease of the somatosensory nervous system.\textsuperscript{20} Studies investigating visceral or cancer pain will be excluded. No restriction is placed on the sex of participants. The duration of pain experienced by participants should be greater than 3 months as this duration is commonly defined as the chronic phase of pain.\textsuperscript{21} Cross-sectional or prospective studies will be included in the initial search if they meet the eligibility criteria. Prospective studies including case–control and randomised controlled trials will only be included if their baseline data provide information relevant to the review objective.

**Inclusion criteria**

1. Full-text studies, including in press or accepted studies, published in English prior to May 2015.

2. Studies conducted on adult humans with chronic non-neuropathic or neuropathic pain.

3. Studies that investigate the organisation and/or function of the M1 (regardless of the anatomical or functional definition used) with the following techniques: TMS, MRI, positron emission tomography, EEG and magnetoencephalography.

4. Studies including data from a healthy control group.

**Exclusion criteria**

1. Studies including participants with chronic pain not of musculoskeletal origin, for example, pain associated with spinal cord injury, stroke, cancer or visceral pain.

2. Studies that do not include a healthy control group or that use the unaffected limb or body side as a control. It is recognised that widespread symptoms remote from the original injury site can be observed in chronic pain.\textsuperscript{22} Thus, using an unaffected limb or body side as a comparison is not considered an appropriate control.

**Primary outcomes**

Eligible studies should report one of the following measurements of M1 organisation and/or function: cortical excitability, spatial representations, inhibitory or...
facilitatory intracortical networks, reactivity and/or glucose metabolism as outcomes for analysis in this review. Clinical measures such as pain and disability will be included where these are correlated with the primary outcomes of M1 organisation and function.

Data management
Two reviewers will independently evaluate the title and abstract of all studies identified through the search against the inclusion and exclusion criteria. Any duplicate studies will be removed. The full text of all eligible studies will then be retrieved. EndNote X7 will be used during the review process to avoid duplicating references. If the reviewer is uncertain about the eligibility of any study, its full text will be obtained for further information. An additional reviewer will be consulted should there be any uncertainty or disagreement of the eligibility of studies. Excluded studies and the reasons for exclusion will be recorded.

Data extraction
A customised data extraction form (see online supplementary appendix 2) will be piloted on two studies not directly related to this review, and then used to extract data. Two independent reviewers will conduct data extraction. Any disagreements will be resolved through an additional reviewer. The following data will be extracted: (1) participant-specific data such as condition, duration and severity of chronic pain, sample size in each group, sex and age; (2) neurophysiological methods and outcomes, specifics of the investigative model such as type and location of stimulation, how M1 was anatomically or functionally defined, neuroimaging findings in M1 excitability, representation, reactivity and glucose metabolism; (3) pain scores. Other outcome measurements such as quantitative sensory tests and movement dysfunction will be extracted if they are correlated with the primary outcomes. If data are missing, authors will be contacted a maximum of three times, after which the data will be considered irretrievable.

Risk of bias (quality) assessment
To assess the risk of bias of the included studies, we will use the STROBE statement for cross-sectional and cohort studies (see online supplementary appendix 3) and items relevant to case–control studies from the Cochrane Collaboration tool for assessing the risk of bias.25 Methodological quality pertaining directly to the use of TMS will be assessed via a TMS methodological checklist (see online supplementary appendix 4).26 Two independent reviewers will undertake the assessment of risk of bias and methodological quality. Any disagreement will be resolved by a third reviewer.

Strategy for data synthesis
A quantitative synthesis is planned to aggregate the data from all types of chronic pain conditions. Parameters such as cortical excitability (resting or active motor thresholds, intracortical inhibition, intracortical facilitation), spatial representation (map volume, BOLD response), M1 reactivity or M1 glucose metabolism will be pooled to perform separate meta-analyses using OpenMetaAnalyst. Cohen’s d effect sizes will be used to analyse effect estimates: d ≤ 0.2 is small, 0.5 represents medium, ≥ 0.8 is considered large.27 Data will be pooled for an outcome by using a random-effects model if data from at least two studies addressing that outcome are accessible. The χ2 test will be used to identify statistically significant heterogeneity, and statistically significant heterogeneity will be considered existent when χ2 p < 0.10. The I2 statistic will be used to evaluate the degree of heterogeneity. Substantial heterogeneity will be considered existent when I2 > 50%.28 All data will be presented as effect estimates (with 95% CIs). Where quantitative synthesis of the extracted data is not appropriate, a narrative synthesis will be used to summarise the study findings about functional and structural changes of M1.17

Analysis of subgroups or subsets
Where significant heterogeneity is found, we will conduct subgroup analysis according to the type of pain conditions (LBP, CRPS, fibromyalgia, peripheral neuropathic pain or peripheral tendinopathy), duration of pain, sex of participants and type of treatment participants were receiving at the time cortical data were collected.

Sensitivity analysis
The included studies will be given a score when assessing their methodological quality. For example, studies will score one point if they meet the criteria of 1 of the 22 items from the STROBE statement, hence a maximum of 22 points can be scored. The median value of the overall scores of eligible studies will be used as the cut-off point to divide the studies into either the low or high risk of bias group. We will then examine the influence of including studies at high risk of bias by running the analysis with those studies excluded.

Twitter Follow Siobhan Schabrun at @DrSMSchabrun

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
REFERENCES


